Wedbush Forecasts Nuvation Bio’s Q1 Earnings (NYSE:NUVB)

Nuvation Bio Inc. (NYSE:NUVB) – Wedbush issued their Q1 2026 earnings per share estimates for Nuvation Bio in a report released on Thursday, March 6th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.23) for the quarter. Wedbush has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.21) EPS.

Several other equities analysts also recently issued reports on the stock. HC Wainwright dropped their price target on shares of Nuvation Bio from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 target price (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $8.00.

Nuvation Bio Price Performance

NYSE:NUVB opened at $2.31 on Monday. Nuvation Bio has a one year low of $1.67 and a one year high of $4.16. The company has a market cap of $775.79 million, a PE ratio of -1.06 and a beta of 1.47. The firm’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $2.57.

Institutional Investors Weigh In On Nuvation Bio

Institutional investors have recently modified their holdings of the company. Forum Financial Management LP bought a new position in Nuvation Bio during the fourth quarter worth $29,000. Cerity Partners LLC bought a new stake in shares of Nuvation Bio in the 4th quarter valued at $31,000. Russell Investments Group Ltd. increased its stake in Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock valued at $42,000 after purchasing an additional 15,791 shares in the last quarter. Abacus Planning Group Inc. bought a new stake in Nuvation Bio during the 4th quarter valued at $44,000. Finally, Cibc World Markets Corp bought a new stake in Nuvation Bio during the fourth quarter worth $45,000. 61.67% of the stock is owned by institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.